

PROTOCOLS, MEDICATIONS, AND DEVICES COMMITTEE
MEETING MINUTES
150 N. 18th Ave., Suite 540A
Phoenix, Arizona
February 16, 2006

Members Present

John Gallagher Terry Shine (teleconference)
Janine Anderson Patricia Ellis (teleconference)
Terence Mason
Rob Jarvis

Members Absent

Charles Finch
Marc Holyfield
Sue Kern
Steven Curry

I. CALL TO ORDER

Meeting was called to order at 1:05 p.m. A quorum was present.

II. DISCUSS/AMEND and ACTION ON THE MINUTES OF SEPTEMBER 15, 2005

A motion was made by Patricia Ellis and seconded by Terence Mason to approve the minutes of September 15, 2005. **Motion carried**

III. OLD BUSINESS:

- A. Discussion and Action on Adopting Drug Profile as Guidance Document for Vaponefrin

A motion was made by John Gallagher and seconded by Rob Jarvis to table this item for the next PMD Committee meeting. Kay Lewis was asked by Dr. Gallagher to prepare the drug profile.

Motion carried

Item: **Drug profile for Vaponefrin**
Follow Up: **Next PMD Committee Meeting**
When: **May 11, 2006**
Who: **Kay Lewis**

- B. Discussion and Action on Continuous Positive Airway Pressure (CPAP) Device
Greg Wood, President and CEO of Emergent Respiratory Products, addressed the Committee regarding CPAP.

Mr. Wood reported that a study was conducted in December 2005.

A motion was made by Patricia Ellis and seconded by Terence Mason to table this item for the next PMD Committee meeting after reviewing information and data to be forwarded by from Emergent Respiratory Products.

Motion carried

Item: Discussion and Action on Continuous Positive Airway Pressure (CPAP) Device
Follow Up: Next PMD Committee Meeting
When: May 11, 2006
Who: Dr. Gallagher

- A. Follow up on drug box requirement to carry Verapamil and Diltiazem.
It was reported that currently Verapamil is required and Diltiazem is optional. However, when the rule is revised it will state Verapamil or Diltiazem.
- B. Follow up on question posed concerning the use of pelvic binders as an alternative to pneumatic anti-shock garments.
It was reported that using the pelvic binder is acceptable and would not be contrary to rule.

IV. NEW BUSINESS:

- A. Discussion and Action of PMD Committee Bylaws
The Committee was asked to review and amend the bylaws for the PMD Committee. A motion was made by Rob Jarvis and seconded by Terence Mason to accept the PMD Committee Bylaws with the following corrections:
 - Article 1, number 9 to read "Recommend treatment guidelines approved for prehospital use."
 - Article 1, number 2 to read "Publish as necessary, agents list approved for prehospital use emphasizing agent minimum supply."
 - Article 5, section 5 to read "A simple majority of the members of the Committee in person or by telephone shall constitute a quorum. PMD consists of 10 membership positions; 6 members must be present in person or by telephone to constitute a quorum."

Motion carried

- B. Review/Discussion of Substantive Policy Statement on Approval of Medical Devices
The Committee reviewed and discussed the document. No changes were necessary.
- C. Discussion on Attorney General Opinion No. I05-004 (R05-010) Re: Open Meeting Law Requirements and E-mail To and From Members of the Public Body
Dr. Gallagher briefly explained the AG Opinion.
- D. Discussion/Approval of 2006 PMD Meeting Dates
A motion was made by Terry Shine and seconded by Patricia Ellis to approve the 2006 PMD Committee meeting dates.

A suggestion was made to move the Education Committee meetings to meet in the morning on the same day as the PMD Committee. The option to move the day of the meeting will be discussed in the next Education Committee meeting.

- E. Report on status of rule revision of R9-25-503 (Drug Box rule) and discussion/action on inclusion of the following drugs:

- a. Lorazepam
- b. Promethazine
- c. Tagamet (transport list)
- d. Terbutaline (transport list)
- e. Toradol
- f. Compazine
- g. Tylenol elixir
- h. Racemic Epinephrine

The Committee members were tasked to review the following and report back at the next PMD Meeting.

- Lorazepam (Patricia Ellis)
- Promethazine (Terence Mason)
- Tagamet (Janine Anderson)
- Toradol (Patricia Ellis)
- Compazine (Terence Mason)

PMD will not make a recommendation for inclusion of Terbutaline, Tylenol Elixir, and Racemic Epinephrine in the Drug Box rule (R9-25-503) at this time. Racemic Epinephrine is already included in the current Exhibit 3 as Vaponefrin.

Item: Discussion and Action on the list of drugs
Follow Up: Next PMD Committee Meeting
When: May 11, 2006

V. CALL TO THE PUBLIC
 No one came forward.

VI. SUMMARY OF CURRENT EVENTS
 No report was given.

VII. ANNOUNCEMENT OF NEXT MEETING – May 11, 2006

VIII. ADJOURNMENT
 Meeting was adjourned at 1:45 p.m.

Minutes prepared by: Amanda Valenzuela
 Approved by Committee: _____